Solid Biosciences

Filgrastim is a monoclonal antibody (mAb) therapeutic candidate in Phase 3 development for lymphoma, sponsored by Solid Biosciences. The program is identified by internal code CDR0000067665 and is currently active. Filgrastim is a granulocyte colony-stimulating factor (G-CSF) analog approved globally under multiple brand names including NIVESTIM. The drug is classified within the antineoplastic and immunomodulating agents therapeutic class (L03). Regulatory approval has been established in Australia (TGA), the European Union (EMA), and the United States (FDA/BLA103353 by Amgen). The latest disclosed milestone dates to September 2013. The program is supported by two clinical trial identifiers (NCT00005589 and NCT00025636), though specific trial details and endpoints remain not yet disclosed. Peak sales projections, consensus positioning, and mechanism of action specifics are not yet disclosed. The competitive landscape includes multiple approved immunomodulatory agents such as Plerixafor ARX, Lonquex, Mepact, and interferon-based therapies.

Lymphoma represents a significant oncology indication with substantial unmet medical needs, particularly in managing treatment-related complications such as chemotherapy-induced neutropenia. Filgrastim's mechanism as a G-CSF analog addresses a critical supportive care need in cancer therapy, enabling dose intensification and reducing infection risk in immunocompromised patients. The Phase 3 development status indicates advancement toward potential label expansion or new indication approval. Market relevance is substantial given the established global approval footprint across Australia, EU, and US markets, with multiple manufacturers (Pfizer, Sandoz, Amgen, Accord Healthcare, and others) indicating competitive market penetration. The therapeutic class encompasses immunomodulating agents with demonstrated clinical utility in hematologic malignancies. Commercial significance is underscored by the presence of multiple PBS codes in Australia (10 distinct codes) and numerous EMA product authorizations (11 EMEA/H/C numbers), suggesting established reimbursement pathways and market access. Competitive positioning against agents such as Plerixafor ARX and Lonquex reflects a crowded supportive care landscape. The patient population encompasses lymphoma patients undergoing chemotherapy, representing a substantial addressable market within oncology. Solid Biosciences' sponsorship of this Phase 3 program suggests strategic focus on hematologic malignancy support, though partnership details remain not yet disclosed.

Drug Class: Antineoplastic and immunomodulating agent (ATC L03); granulocyte colony-stimulating factor (G-CSF) analog.

Modality: Monoclonal antibody (mAb).

Molecular Target: Not yet disclosed.

Mechanism of Action: Not yet disclosed; however, filgrastim is established as a G-CSF receptor agonist that stimulates proliferation and differentiation of hematopoietic progenitor cells, reducing chemotherapy-induced neutropenia.

Route of Administration: Not yet disclosed in this program profile.

Brand Names: NIVESTIM (primary disclosed brand).

Related Therapies: Pegfilgrastim (longer-acting G-CSF analog), lenograstim, molgramostim, and plerixafor (CXCR4 antagonist for mobilization).

First Approval: Filgrastim was first approved by the FDA (BLA103353, Amgen). Australian TGA approval dates range from August 2011 onwards across multiple sponsors. EMA authorizations span multiple product numbers with dates through 2026.

Patent Status: Not yet disclosed.

United States (FDA): Filgrastim approved under BLA103353 (Amgen). Current program status and any new indication filings not yet disclosed.

European Union (EMA): Multiple filgrastim products authorized across 11 distinct EMEA/H/C numbers (EMEA/H/C/000824, 000825, 000826, 000827, 000917, 000918, 001142, 002150, 003956, 005888, 006400) with marketing authorization holders including Pfizer Europe MA EEIG, Sandoz GmbH, Hexal AG, Accord Healthcare S.L.U., Ratiopharm GmbH, Teva GmbH, CuraTeQ Biologics s.r.o, and AbZ-Pharma GmbH. Authorization dates span through 2026 (12/02/2026, 12/06/2025, 26/09/2025 most recent).

Australia (TGA): Filgrastim approved with 10 PBS codes (2733W, 2747N, 2758E, 2783L, 5742F, 5744H, 5829T, 5830W, 6291D, 6292E). Sponsors include Pfizer Australia Pty Ltd and Sandoz Pty Ltd with first listed dates from August 2011, September 2013, and October 2019.

Japan (PMDA): Status not yet disclosed.

China (NMPA): Status not yet disclosed.

Strategic Implications: Solid Biosciences' Phase 3 filgrastim program in lymphoma represents a focused indication expansion strategy within an established therapeutic class. The 2013 milestone date suggests a mature program; however, the absence of disclosed trial results or regulatory filing status raises questions regarding development velocity and commercial prioritization. The mAb modality designation warrants clarification, as filgrastim is traditionally a recombinant protein, not a monoclonal antibody—this may indicate a novel formulation, conjugate, or derivative approach not yet disclosed.

Competitive Implications: The filgrastim market is highly commoditized globally, with multiple approved biosimilars and generics from major manufacturers (Pfizer, Sandoz, Amgen, Accord). Solid Biosciences' entry into lymphoma support therapy faces significant generic competition and established clinical practice patterns. Differentiation through improved pharmacokinetics, reduced injection frequency, or enhanced safety profile would be required to justify premium positioning against commoditized alternatives.

Future Catalysts: Key catalysts include disclosure of Phase 3 trial results, regulatory filing in major markets, label expansion approval, and commercial partnership announcements. Expected next milestone timing and label remain not yet disclosed.

Expected Milestones: Anticipated catalysts include Phase 3 completion and top-line data readout, regulatory submission to FDA/EMA, and potential approval decision within 12–24 months if development remains on track. Peak sales projections and consensus positioning are not yet disclosed, limiting commercial forecasting.